Physician profile
Michael Margolis
NPI 1780844522
$3,747.09
in general payments reported to CMS, 2019-2025
25 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.22 · 2020: $60.76 · 2021: $121 · 2023: $732 · 2024: $1,439 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,500.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $923.37 | 2023-2025 | |
| Biotissue Holdings INC. | $594.58 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $550.24 | 2023-2025 | Acthar |
| Bausch & Lomb Americas INC. | $312.89 | 2024-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Dutch Ophthalmic, USA | $273.82 | 2023 | Eva, Combined Machine, Tissueblue |
| Alcon Vision LLC | $195.37 | 2024-2025 | Rocklatan |
| Tarsus Pharmaceuticals, INC. | $193.11 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $98.21 | 2025 | Streamline, Clearpath, Via360 |
| Thea Pharma INC. | $95.41 | 2023-2025 | Iyuzeh |
| Takeda Pharmaceuticals U.S.A., INC. | $70.86 | 2021 | |
| Sun Pharmaceutical Industries INC. | $63.72 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $56.83 | 2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $44.71 | 2020 | |
| Ani Pharmaceuticals, INC. | $31.26 | 2023 | Purified Cortrophin Gel |
| Dompe US, INC. | $29.45 | 2024 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $29.36 | 2024 | Omni Surgical System |
| Antares Pharma, INC. | $28.63 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $26.80 | 2024 | Tecnis Iol |
| Glaukos Corporation | $26.01 | 2024 | Ce-Marked Kxla System |
| Abbott Laboratories | $19.47 | 2021 | |
| Dexcom, INC. | $19.05 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $17.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.37 | 2021 | |
| Rxsight INC | $16.02 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.